Completed

1

21

RoW

Camrelizumab, Humanized anti-PD-1 inhibitor, Apatinib, VEGFR2 inhibitor, Radical surgery, Post-operative radiotherapy/chemoradiotherapy

Shanghai Jiao Tong University School of Medicine

Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy

11/20

11/23

Not yet recruiting

1

38

 

fuzuoparib (PARP inhibitor) in combination with Albumin Palitaxel and Camrelizumab (PD-1 inhibitor)

The General Hospital of the People's Liberation Army (PLAGH); The General Hospital of the People's Liberation Army (PLAGH), scientific research project

advanced solid cancer

 

 

Not yet recruiting

1

30

 

SHR-1210+apatinib

Third Affiliated Hospital of the Second Military Medical University; Third Affiliated Hospital of the Second Military Medical University, Jiangsu Hengrui Pharmaceutical Co. LTD

Intrahepatic Cholangiocarcinoma

 

 

Recruiting

1

20

RoW

Capecitabine, Camrelizumab

Ruijin Hospital

Head and Neck Cancer, Esophageal Squamous Cancer

08/22

08/24

Recruiting

1

20

RoW

Camrelizumab treatment

Third Affiliated Hospital, Sun Yat-Sen University

Hepatocellular Carcinoma, Liver Transplantation

09/22

07/23

Not yet recruiting

1

20

RoW

Capsulized Fecal Microbiota Transplant, Capsulized FMT, Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody, Anti-PD-1/PD-L1 mAb, Anti-PD-1/PD-L1, Pembrolizumab, Nivolumab, Durvalumab, Sintilimab, Tislelizumab, Camrelizumab, Platinum based chemotherapy, Platinum based Chemotherapy drugs

Shanghai Zhongshan Hospital

Non-Small Cell Lung Cancer

12/22

12/22

Enrolling by invitation

1

240

RoW

SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Malignant Tumors

01/23

06/23

Recruiting

1

20

RoW

Capecitabine, Camrelizumab

Ruijin Hospital

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

07/23

07/25

Not yet recruiting

1

80

RoW

HAIC、Bevacizumab、Camrelizumab, Camrelizumab brand name: ai rui ka; Bevacizumab brand name: ai rui tuo

Fudan University

Metastatic Liver Cancer

10/23

10/24

Not yet recruiting

1

30

 

Carrilizumab + albumin-paclitaxel + carboplatin was given. After 2 weeks of treatment, the drug was stopped and lung cancer resection was performed

First Affiliated Hospital of Anhui Medical University; First Affiliated Hospital of Anhui Medical University, None

non-small cell lung cancer (NSCLC)

 

 

Recruiting

1

120

RoW

Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)

The First Affiliated Hospital of Dalian Medical University

Long-Term Effects Secondary to Cancer Therapy

12/24

12/25

Recruiting

1

60

RoW

MASCT-I, Camrelizumab,Apatinib

HRYZ Biotech Co.

Sarcoma

08/24

12/24

Not yet recruiting

1

100

 

Thalidomide combined with carrilizhu

The Third Affiliated Hospital of Shandong First Medical University; The Third Affiliated Hospital of Shandong First Medical University, self-funded

reactive cutaneous capillary endothelial proliferation

 

 

Not yet recruiting

1

64

 

PD-1+Apatinib+Chemotherapy

The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Third Party Funded Drugs

colon cancer

 

 

Not yet recruiting

1

118

 

A single intravenous administration of 20 mg was performed, and 12 subjects were randomly divided into 1:1 groups to receive carrilizumab (old process) and carrilizumab (new process) at random. The pre-trial study procedure was the same as the formal trial. ;A single intravenous administration of 20 mg was performed, and 12 subjects were randomly divided into 1:1 groups to receive carrilizumab (old process) and carrilizumab (new process) at random. The pre-trial study procedure was the same as the formal trial. ;Test preparation (T) was a new process of carrilizumab; The reference preparation (R) was the old process carrilizumab. Using a single intravenous administration of 20 mg, 106 healthy male subjects were randomly divided into 1:1 groups to receive carrilizumab (old process) and carrilizumab (new process), and the formal trial study process was the same as the preliminary trial. ;Test preparation (T) was a new process of carrilizumab; The reference preparation (R) was the old process carrilizumab. Using a single intravenous administration of 20 mg, 106 healthy male subjects were randomly divided into 1:1 groups to receive carrilizumab (old process) and carrilizumab (new process), and the formal trial study process was the same as the preliminary trial.

Clinical Trial Center of Third Xiangya Hospital of Central South University; Third Xiangya Hospital, Central South University, Suzhou Shengdia Biomedicine Co., LTD

Malignant tumor